Idera Pharmaceuticals Inc. (Nasdaq: IDRA) reported positive results from a Phase 2 trial of its psoriasis treatment IMO-8400 sending the stock price up 64 cents to $4.52.
Idera Reports Positive Trial Results
March 28, 2014 at 14:48 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.